Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Loans - Net Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Perspective Therapeutics (CATX) Receivables - Other (2016 - 2025)

Perspective Therapeutics' Receivables - Other history spans 15 years, with the latest figure at $10000.0 for Q4 2025.

On a quarterly basis, Receivables - Other fell 97.95% to $10000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $10000.0, a 97.95% decrease, with the full-year FY2025 number at $10000.0, down 97.95% from a year prior.
Receivables - Other hit $10000.0 in Q4 2025 for Perspective Therapeutics, down from $487000.0 in the prior quarter.
Over the last five years, Receivables - Other for CATX hit a ceiling of $487000.0 in Q4 2024 and a floor of $2000.0 in Q4 2022.
Historically, Receivables - Other has averaged $93000.0 across 5 years, with a median of $13500.0 in 2022.
Biggest five-year swings in Receivables - Other: soared 4770.0% in 2024 and later tumbled 97.95% in 2025.
Tracing CATX's Receivables - Other over 5 years: stood at $32000.0 in 2021, then tumbled by 93.75% to $2000.0 in 2022, then surged by 400.0% to $10000.0 in 2023, then soared by 4770.0% to $487000.0 in 2024, then tumbled by 97.95% to $10000.0 in 2025.
Business Quant data shows Receivables - Other for CATX at $10000.0 in Q4 2025, $487000.0 in Q4 2024, and $10000.0 in Q4 2023.